Table 1 Patient characteristics and biomarkers
Patients characteristics | Median or N (range or %) |
|---|---|
Sex | |
 Male | 86 (61.4) |
 Female | 54 (38.6) |
Age | 63.0 (27.0–85.0) |
Number of previous treatments | 1 (0–4) |
Follow-up (months) | 9.8 (2.4–53.6) |
Biomarker (normal range) | Median (range) |
|---|---|
White blood cells (4.40–11.00 × 106/L) | 6.2 (2.3–17.5) |
Eosinophils (0–0.50 × 106/L) | 0.08 (0.01–0.89) |
Neutrophils (1.80–7.8 × 106/L) | 4.0 (1.1–16.2) |
Lymphocytes (1.10–4.80 × 106/L) | 1.3 (0.7–2.5) |
 CD3+ (7.0–27.0%) | 71.0 (42.0–92.0) |
 CD4+ (32–52%) | 39.0 (17.0–73.0) |
 CD8+ (16–33%) | 23.0 (5.3–79.0) |
 NK (7.0–27.0%) | 18.0 (5.6–35.6) |
 CD3/CD16/CD56+ (1–11%) | 3.0 (1.0–13.0) |
LDH (< 1, × UNL) | 0.9 (0.4–11.56) |
CRP (0–6 mg/L) | 6.7 (2.9–214.0) |
β2-microglobulin (1.09–2.53 ng/L) | 2.3 (1.2–7.2) |
IL6 (0–5.9 ng/L) | 3.5 (2.0–658.0) |
IL2 (0–2 ng/L) | 7 (2–28.3) |
S-100 (0.00–0.15 μg/L) | 0.6 (0.03–97.0) |
VEGF (62–707 ng/L) | 431.5 (3.4–2100.0) |